Skip to main content
. 2016 Mar 4;7(15):20080–20092. doi: 10.18632/oncotarget.7914

Figure 6. ABC294640 in combination with sorafenib synergistically inhibits proliferation in cholangiocarcinoma cells.

Figure 6

(A) HuCCT1 and WITT cells were treated with different fixed-ratio combinations of ABC294640 and sorafenib and proliferation was determined by BrdU ELISA assay. The results are presented as mean ± SEM from at least three independent experiments. The combination index (CI) was determined using the Chou-Talalay Method. CI < 1 indicates that the interaction between ABC294640 and sorafenib was synergistic. (B) HuCCT1 and WITT cells were treated with 40 μM ABC294640 (ABC) and/or 6 μM sorafenib (Sor) for 24 h and whole cell lysates were then subjected to immunoblotting.